Loading clinical trials...
Loading clinical trials...
A Phase II, Prospective, Open-Label Study to Evaluate the Efficacy and Safety of Dapagliflozin for Anemia in Patients With Lower-Risk Myelodysplastic Syndromes
Conditions
Interventions
Dapagliflozin (10mg Tab)
Start Date
September 1, 2026
Primary Completion Date
January 1, 2029
Completion Date
September 1, 2029
Last Updated
April 8, 2026
NCT07039422
NCT06465953
NCT05012111
NCT03520647
NCT04304820
NCT05447442
Lead Sponsor
Seug yun Yoon, MD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions